Cargando…
Postauthorization safety surveillance study of antihaemophilic factor (recombinant) reconstituted in 2 mL sterile water for injection in children with haemophilia A
INTRODUCTION: Antihaemophilic factor (recombinant) (rAHF; ADVATE(®)) is approved for prophylaxis and treatment of bleeding in children and adults with haemophilia A. Reconstitution in 2 mL sterile water for injection instead of 5 mL allows for a 60% reduction in infusion volume and administration ti...
Autores principales: | Motwani, Jayashree, Guillet, Benoit, Blatny, Jan, Schilling, Freimut H., Wibaut, Bénédicte, Goldstine, Jimena, Nagy, Andras, Doralt, Jennifer, Engl, Werner, Tangada, Srilatha, Spotts, Gerald |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7383916/ https://www.ncbi.nlm.nih.gov/pubmed/32338433 http://dx.doi.org/10.1111/hae.13997 |
Ejemplares similares
-
Results of a randomized phase III/IV trial comparing intermittent bolus versus continuous infusion of antihaemophilic factor (recombinant) in adults with severe or moderately severe haemophilia A undergoing major orthopaedic surgery
por: Pabinger, Ingrid, et al.
Publicado: (2021) -
Perioperative haemostasis with full‐length, PEGylated, recombinant factor VIII with extended half‐life (rurioctocog alfa pegol) in patients with haemophilia A: Final results of a multicentre, single‐arm phase III trial
por: Gruppo, Ralph, et al.
Publicado: (2019) -
Long‐term joint outcomes in adolescents with moderate or severe haemophilia A
por: Schmidt, David E., et al.
Publicado: (2022) -
European principles of inhibitor management in patients with haemophilia
por: Giangrande, P. L. F., et al.
Publicado: (2018) -
Social support and resilience in persons with severe haemophilia: An interpretative phenomenological analysis
por: Ratajová, Kateřina, et al.
Publicado: (2020)